Journal
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
Volume 10, Issue 4, Pages 259-266Publisher
SPRINGER
DOI: 10.1007/s11910-010-0111-9
Keywords
Malignant glioma; Immunotherapy; Review; Clinical trial; Glioblastoma multiforme; Cancer; Treatment
Categories
Funding
- NCI NIH HHS [P50 CA108786] Funding Source: Medline
- NINDS NIH HHS [P50 NS020023] Funding Source: Medline
Ask authors/readers for more resources
Malignant glioma is a deadly disease for which there have been few therapeutic advances over the past century. Although previous treatments were largely unsuccessful, glioma may be an ideal target for immune-based therapy. Recently, translational research led to several clinical trials based on tumor immunotherapy to treat patients with malignant glioma. Here we review 17 recent glioma immunotherapy clinical trials, published over the past 3 years. Various approaches were used, including passive transfer of naked and radiolabeled antibodies, tumor antigen-specific peptide immunization, and the use of patient tumor cells with or without dendritic cells as vaccines. We compare and discuss the current state of the art of clinical immunotherapy treatment, as well as its limited successes, pitfalls, and future potential.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available